Medication Monitor



Generic Name (Trade Name—Company)
Notes
October 31, 2019

Minocycline

(Amzeeq—Foamix)
First topical formulation of minocycline approved to treat acne

On October 18, FDA approved minocycline topical foam, 4%, a tetracycline-class drug that targets inflammatory lesions of nonnodular moderate to severe acne vulgaris in adults and pediatric patients ages 9 years and older. It is the first topical minocycline to be approved by FDA for any condition.

Minocycline is a broad-spectrum antibiotic known for its efficacy in treating moderate to severe acne, but its use is limited in some patients because of systemic adverse effects when taken orally. Until now, minocycline has not been available as a topical treatment because of its instability in traditional topical formulations.

The recommended dosage is to apply to affected areas once daily. The foam should be gently rubbed into the skin.

Minocycline topical foam is expected to be available for prescribing in January 2020.

Headache was the most common adverse reaction reported during clinical trials.